1
|
Egri N, Bentow C, Rubio L, Norman GL, López-Sañudo S, Mahler M, Pérez-Isidro A, Cervera R, Viñas O, Espinosa G, Ruiz-Ortiz E. Anti-Phosphatidylserine/Prothrombin Antibodies at Two Points: Correlation With Lupus Anticoagulant and Thrombotic Risk. Front Immunol 2021; 12:754469. [PMID: 34790198 PMCID: PMC8592011 DOI: 10.3389/fimmu.2021.754469] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Accepted: 09/29/2021] [Indexed: 01/18/2023] Open
Abstract
Antibodies to phospholipids (aPL) and associated proteins are a hallmark in the diagnosis of anti-phospholipid syndrome (APS). Those included in the classification criteria are the lupus anticoagulant (LA) and the IgG and IgM isotypes of anticardiolipin (aCL) and anti-beta-2 glycoprotein I (β2GPI) antibodies. Non-classification criteria markers such as autoantibodies that recognize the phosphatidylserine/prothrombin (aPS/PT) complex have been proposed as biomarkers for APS. Studies of aPS/PT antibodies have shown a strong correlation to clinical manifestations and LA. We aimed to study the value and the persistence of aPS/PT IgG and IgM antibodies in a cohort of consecutive patients with clinical suspicion of APS and their utility as thrombotic risk markers. Our study, with 103 patients, demonstrates that persistently positive results for aPS/PT IgG antibodies were significantly associated with APS classification, thrombosis, triple aPL positivity, LA positive result, and the Global APS Score (GAPSS) > than 9 points (p < 0.01, for each condition). On the other hand, no association was seen with pregnancy morbidity (p = 0.56) and SLE (p = 0.07). Persistence of aPS/PT antibodies, defined according to the current laboratory classification criteria, likely improves the diagnosis and clinical assessment of patients with APS.
Collapse
Affiliation(s)
- Natalia Egri
- Institut de Recerca Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Immunology, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Chelsea Bentow
- Headquarters & Technology Center, Autoimmunity, Werfen, San Diego, CA, United States
| | - Laura Rubio
- Department of Immunology, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Gary L Norman
- Headquarters & Technology Center, Autoimmunity, Werfen, San Diego, CA, United States
| | | | - Michael Mahler
- Headquarters & Technology Center, Autoimmunity, Werfen, San Diego, CA, United States
| | - Albert Pérez-Isidro
- Institut de Recerca Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Immunology, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Ricard Cervera
- Institut de Recerca Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Autoimmune Diseases, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Odette Viñas
- Institut de Recerca Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Immunology, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Gerard Espinosa
- Institut de Recerca Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Autoimmune Diseases, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Estíbaliz Ruiz-Ortiz
- Institut de Recerca Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Immunology, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, Spain
| |
Collapse
|
2
|
Rodríguez-Sánchez MN, Puebla L, López-Sañudo S, Rodríguez-Martín E, Martín-Espinosa A, Rodríguez-Pena MS, Juarranz MG, Arilla E. Dopamine enhances somatostatin receptor-mediated inhibition of adenylate cyclase in rat striatum and hippocampus. J Neurosci Res 1997; 48:238-48. [PMID: 9160246 DOI: 10.1002/(sici)1097-4547(19970501)48:3<238::aid-jnr6>3.0.co;2-g] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Although there is evidence that suggests that dopamine (DA) has stimulatory effects on somatostatinergic transmission, it is unknown to date if DA increases the activity of the somatostatin (SS) receptor-effector system in the rat brain. In this study, we evaluated the effects of the administration of DA and the DA D1-like (D1, D5) receptor antagonist SCH 23390 and the D2-like (D2, D3, D4) receptor antagonist spiperone on the SS receptor-adenylate cyclase (AC) system in the Sprague-Dawley rat striatum and hippocampus. An intracerebroventricular injection of DA (0.5 microgram/rat) increased the number of SS receptors and decreased their apparent affinity in the striatum and hippocampus 15 hr after its administration. The simultaneous administration of the DA receptor antagonists SCH 23390 (0.25 mg/kg, ip) and spiperone (0.1 mg/kg, ip) before DA injection partially prevented the DA-induced increase in SS binding. The administration of SCH 23390 plus spiperone alone produced a significant decrease in the number of SS receptors in both brain areas studied at 15 hr after injection, an effect that disappeared at 24 hr. The increased number of SS receptors in the DA-treated rats was associated with an increased capacity of SS to inhibit basal and forskolin (FK)-stimulated (AC) activity in the striatum and hippocampus at 15 hr after injection. This effect had disappeared at 24 hr. By contrast, basal and FK-stimulated enzyme activities were unaltered after DA injection. No significant changes in the levels of the alpha i (alpha i1 + alpha i2) subunits were found in DA-treated rats as compared with control rats. In addition, the immunodetection of the alpha i1 or alpha i2 subunits showed no significant changes in their levels in DA-treated rats when compared with controls. DA injection also induced an increase in SS-like immunoreactive content in the rat striatum but not hippocampus at 15 hr after administration and returned to control values at 24 hr. These results provide direct evidence of a functional linkage between the dopaminergic and somatostatinergic systems at the molecular level.
Collapse
Affiliation(s)
- M N Rodríguez-Sánchez
- Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Alcalá de Henares, Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
3
|
López-Sañudo S, Puebla L, Guijarro LG, Prieto JC, Arilla E. Alpha-2 adrenoceptors modulate the somatostatinergic system and G protein levels in the rat hippocampus. Neuropsychopharmacology 1995; 12:47-55. [PMID: 7766286 DOI: 10.1038/sj.npp.1380238] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
alpha 2-Adrenoceptor agonists and somatostatin (SS) exert opposite effects on the spike discharge of pyramidal and granule cells in the rat hippocampus. We studied whether clonidine, an alpha 2-adrenoceptor agonist, and yohimbine, an alpha 2-adrenoceptor antagonist, can modulate somatostatin-like immunoreactivity (SSLI) levels, binding of 125I-Tyr11-somatostatin (125I-Tyr11-SS) to its specific receptors, SS-inhibited adenylyl cyclase (AC) activity, and the guanine-nucleotide binding regulatory proteins Gi and G(o) in the rat hippocampus. Clonidine (1 mg/kg, intraperitoneally (IP) or yohimbine (5 mg/kg, IP) injected at both 10 and 16 hours before decapitation did not affect SSLI content in the hippocampus. Clonidine administration decreased the number of specific SS receptors and increased the apparent affinity in hippocampal membranes. This change in SS binding was not the result of a direct effect of clonidine on these receptors because no effect in binding was produced by high concentrations of clonidine (10(-5) M) when added in vitro. Pretreatment with yohimbine prevented the clonidine-induced in SS binding. Yohimbine alone produced a significant increase in the number of 125I-Tyr11-SS receptors and a decrease in its apparent affinity. Clonidine decreased the ADP-ribosylation of a 41- and a 39-kDa G-protein by pertussis toxin (PTX), whereas yohimbine had no effect on the PTX-catalyzed ADP-ribosylation. No significant differences were seen for the basal or for the forskolin (FK)-stimulated AC enzyme activities in the control, clonidine- and/or yohimbine-treated groups. Somatostatin caused a significantly lower inhibition in AC activity in hippocampal membranes of clonidine-treated rats, whereas yohimbine led to an opposite effect.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- S López-Sañudo
- Facultad de Medicina, Universidad de Alcalá, Madrid, Spain
| | | | | | | | | |
Collapse
|
4
|
Abstract
Somatostatin (SS) and noradrenaline (NA) are distributed in the rat cerebral cortex, and seizure activity is one of the aspects of behavior affected by both neurotransmitters. Due to the possible interaction between both neurotransmitter systems, we studied whether phenylphrine, an alpha 1-adrenoceptor agonist, and prazosin, an alpha 1-adrenoceptor antagonist, can modulate SS-like immunoreactivity (SS-LI) levels, binding of [125I][Tyr11]SS to its specific receptors, the ability of SS to inhibit adenylate cyclase (AC) activity, and the guanine nucleotide binding regulatory protein G, and G., in the Sprague-Dawley rat frontoparietal cortex. An IP dose of 2 or 4 mg/kg of phenylephrine injected 7 h before decapitation decreased the number of SS receptors and increased the apparent affinity in frontoparietal cortex membranes. An IP dose of 20 or 25 mg/kg of prazosin administered 8 h before decapitation increased the number of SS receptors and decreased their apparent affinity. The administration of prazosin before the phenylephrine injection prevented the phenylephrine-induced changes in SS binding. The addition of phenylephrine and/or prazosin 10(-5) M to the incubation medium changed neither the number nor the affinity of the SS receptors in the frontoparietal cortex membranes. Phenylephrine or prazosin affected neither SS-LI content nor the basal or forskolin (FK)-stimulated AC activities in the frontoparietal cortex. In addition, SS caused an equal inhibition of AC activity in frontoparietal cortex membranes of phenylephrine-and prazosintreated rats compared with the respective control group. Finally, phenylephrine and prazosin did not vary the pertussis toxin (PTX)-catalyzed ADP ribosylation of Gi- and/or Go-proteins. These results suggest that the above-mentioned changes are related to the phenylephrine activation of alpha 1-adrenoceptors or to the blocking of these receptors by prazosin. In addition, these data provide further support for a functional interrelationship between the alpha 1-adrenergic and somatostatinergic systems in the rat frontoparietal cortex.
Collapse
Affiliation(s)
- S López-Sañudo
- Departmento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Alcalá, Madrid, Spain
| | | | | | | |
Collapse
|
5
|
Abstract
The administration of an i.p. dose of phenylephrine (2 mg/kg) increased the number of [125I]Tyr11-somatostatin ([125I]Tyr11-SS) receptors and decreased their apparent affinity in rat hippocampal membranes 7 h after its injection. Prazosin (20 mg/kg, i.p.) administered 1 h before phenylephrine reversed effects of the latter on SS binding. Prazosin alone decreased the number of SS receptors without changing the affinity. The addition of phenylephrine or prazosin (10(-5) M) to the incubation medium did not change the SS binding characteristics. The present results support the notion that the alpha 1-adrenergic system regulates the binding of SS to its specific receptors in rat hippocampus.
Collapse
Affiliation(s)
- S López-Sañudo
- Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Alcalá, Madrid, Spain
| | | |
Collapse
|
6
|
López-Sañudo S, Arilla E. Somatostatin receptors coupled to the inhibition of adenylyl cyclase in the rat frontoparietal cortex are modulated by alpha 2 adrenoceptors. Brain Res Mol Brain Res 1994; 25:143-6. [PMID: 7984040 DOI: 10.1016/0169-328x(94)90290-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The administration of an alpha 2-adrenoceptor agonist, clonidine, increased the number of somatostatin (SS) receptors and the affinity constant in frontoparietal cortex membranes. In addition, in the clonidine group, the capacity of SS to inhibit basal and forskolin (FK)-stimulated adenylyl cyclase (AC) activity in the frontoparietal cortex was significantly higher than in the control group. Pretreatment with the alpha 2-adrenoceptor antagonist yohimbine prevented the clonidine-induced changes in SS binding and SS-inhibited AC activity. Yohimbine alone had an opposite effect from clonidine. These experiments provide further evidence that the alpha-adrenergic system modulates the rat frontoparietal cortex somatostatinergic system.
Collapse
Affiliation(s)
- S López-Sañudo
- Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Alcalá, Madrid, Spain
| | | |
Collapse
|
7
|
López-Sañudo S, Arilla E. Beta-adrenergic regulation of the somatostatinergic system in rat hippocampus. Neurosci Lett 1994; 165:27-32. [PMID: 7912420 DOI: 10.1016/0304-3940(94)90701-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Interaction of beta-adrenergic and somatostatinergic systems in the hippocampus has not been investigated fully. We studied the influence of DL-isoproterenol (ISO), a beta-adrenergic agonist and DL-propranolol (PRO), a beta-adrenergic blocking agent, on the somatostatinergic system in the rat hippocampus. The short-(5h) and long-term (14 days) administration of ISO (5 mg/kg i.p.) or of PRO (10 mg/kg i.p.) did not affect somatostatin-like immunoreactivity (SSLI) content in the hippocampus of male Wistar rats. Both short- and long-term ISO administration decreased the number of specific [125I]Tyr11-somatostatin ([125I]Tyr11-SS) receptors in synaptosomes from hippocampus (29%, P < 0.05 and 34%, P < 0.05, after short- and long-term administration, respectively) without changing the affinity constant. This decrease in the number of [125I]Tyr11-SS receptors was not due to a direct effect of ISO on these receptors since no decrease in binding was produced by high concentrations of ISO (10(-5) M) when added in vitro. In addition, this decrease could be blocked by pretreatment with PRO. Short- and long-term administration of PRO alone increased the [125I]Tyr11-SS binding in hippocampus (42%, P < 0.05 and 33%, P < 0.05, after short- or long-term administration, respectively) without changing the affinity constant. Although there is no direct evidence that the regulation of SS receptors by the beta-adrenergic system has a physiological significance, this mechanism may provide a means by which the brain environment could modulate SS receptor number and, therefore, sensitivity to SS in a subset of SS-sensitive neurons.
Collapse
Affiliation(s)
- S López-Sañudo
- Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain
| | | |
Collapse
|
8
|
Abstract
DL-Propranolol (PRO), a beta-adrenergic blocking agent, and the neuropeptide somatostatin (SS) have central nervous system depressant and anticonvulsive properties. To investigate a possible relationship between these two components, we studied the influence of PRO and DL-isoproterenol (ISO), a beta-adrenergic agonist, on the somatostatinergic system in the rat frontoparietal cortex. The short- (5 h) and long-term (14 days) administration of ISO (5 mg/kg, intraperitoneally (i.p.)), or of PRO (10 mg/kg, i.p.) did not affect somatostatin-like immunoreactivity (SLI) content in the frontoparietal cortex of male Wistar rats. Both short- and long-term ISO administration decreased the number of specific [125I]Tyr11-SS receptors in synaptosomes from frontoparietal cortex (31%, P < 0.05, and 26%, P < 0.02, after short- and long-term administration, respectively) without changing the affinity constant. This decrease in the number of [125I]Tyr11-SS receptors was not due to a direct effect of ISO on these receptors since no decrease in binding was produced by high concentrations of ISO (10(-5) M) when added in vitro. This decrease could be blocked by pretreatment with PRO. Short- and long-term administration of PRO alone produced an increase in the [125I]Tyr11-SS binding in frontoparietal cortex (26%, P < 0.02, and 40%, P < 0.001, after short- or long-term administration, respectively) without changing the affinity constant.
Collapse
Affiliation(s)
- S López-Sañudo
- Department of Biochemistry and Molecular Biology, Medical School, University of Alcalá, Madrid, Spain
| | | |
Collapse
|
9
|
Abstract
In order to investigate the possibility that, in the rat, some cerebral cortex somatostatin (SS) receptors may be localized presynaptically on the terminals of serotonergic neurons, serotonin [5-hydroxytryptamine, (5-HT)] neurons in the central nervous system were damaged with a local intracerebral injection of the serotonergic neurotoxin, 5,7-dihydroxytryptamine(5,7-DHT). The injection of 5,7-DHT (11 micrograms free base dissolved in 10 microliters of isotonic saline containing 0.01% ascorbic acid) in rats produced an reduction by about 74% in frontoparietal cortical 5-HT content at 1 and 3 weeks after injection. These changes were associated with a significant decrease by about 30% in the total number of specific SS receptors in the frontoparietal cortex at both times studied without influencing the apparent affinity of the receptors. Together, these results suggest that a portion of the frontoparietal cortex SS receptors may be localized presynaptically on the serotonergic nerve terminals. The 5,7-DHT did not affect SS-like immunoreactivity (SSLI) levels suggesting that SS and 5-HT are not colocalized within the same neuronal elements in the rat frontoparietal cortex.
Collapse
Affiliation(s)
- G Muñoz-Acedo
- Department of Biochemistry and Molecular Biology, Medical School, University of Alcalá, Madrid, Spain
| | | | | |
Collapse
|
10
|
López-Sañudo S, Arilla E. Desmethylimipramine pretreatment prevents 6-hydroxydopamine induced somatostatin receptor reduction in the rat hippocampus. Regul Pept 1992; 41:227-36. [PMID: 1438990 DOI: 10.1016/0167-0115(92)90116-c] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Several studies have shown anatomical and functional interconnections between catecholaminergic and somatostatinergic systems. To assess whether somatostatin (SS) may act presynaptically on catecholamine neurons, SS receptors were measured using radioligand test-tube binding assays on synaptosomes from hippocampus and frontoparietal cortex--areas that are innervated by catecholaminergic neurons with different densities and that have a high number of SS receptors--from control and 6-hydroxydopamine (6-OHDA)-treated rats. Intracerebroventricular (i.c.v.) injection of the catecholamine neurotoxin 6-OHDA (0.78 mg free base/kg of body weight in saline with 0.1% ascorbic acid) lowered hippocampal and frontoparietal cortical noradrenaline (NA) and dopamine (DA) levels at 1 week following the injection. Pretreatment of rats with desmethylimipramine (DMI) (40 mg/kg, intraperitoneal) prevented the drop in NA levels, but was not effective in attenuating DA depletion in the two brain areas studied. Treatment with 6-OHDA lowered the number of 125I-Tyr11-SS receptors in the hippocampus (130 +/- 19 vs. 266 +/- 16 fmol/mg protein, P < 0.001), whereas in the frontoparietal cortex a non significant 20% reduction in receptor number was found. The dissociation constants of 125I-Tyr11-SS binding to synaptosomes from frontoparietal cortex (0.65 +/- 0.06 vs. 0.60 +/- 0.04, P not significant) and hippocampus (0.44 +/- 0.04 vs. 0.63 +/- 0.14, P not significant) were similar in control and treated groups. Pretreatment with DMI reversed up to 80% of the effect of 6-OHDA on hippocampus SS receptors. DMI alone had no observable effect on the number and affinity of SS receptors. The 6-OHDA and the DMI treatment did not affect SLI levels in the brain areas studied. These results suggest that a portion of the hippocampal SS receptors may be localized presynaptically on the noradrenergic and dopaminergic nerve terminals.
Collapse
Affiliation(s)
- S López-Sañudo
- Department of Biochemistry and Molecular Biology, Medical School, University of Alcalá, Alcalá de Henares, Madrid, Spain
| | | |
Collapse
|
11
|
Abstract
Several lines of evidence suggest that somatostatin (SS) may interact with serotonergic neurons in the central nervous system. To assess whether SS acts presynaptically on serotonin (5-hydroxytryptamine, (5-HT)) neurons, SS receptors were measured in membranes from the hippocampus, a brain region that receives dense serotonergic innervation and has a high number of SS receptors in control and 5,7-dihydroxytryptamine (5,7-DHT)-treated rats, at 1 and 3 weeks after injection. Intracerebroventricular (i.c.v.) injection of the 5-HT-specific neurotoxin 5,7-DHT (11 micrograms (free base) dissolved in 10 microliters of isotonic saline containing 0.01% ascorbic acid) produced a 70% reduction in hippocampal 5-HT content at 3 weeks after injection but not at 1 week. This change was associated with a significant decrease in SS receptor density in rat hippocampus only at 3 weeks following the injection, without influencing the apparent affinity of the receptors at any time. Administration of 5,7-DHT did not affect somatostatin-like immunoreactivity (SSLI) levels at both times studied. These results suggest that some of the hippocampal SS receptors may be localized presynaptically on the serotonergic nerve terminals.
Collapse
Affiliation(s)
- G Muñoz-Acedo
- Department of Biochemistry and Molecular Biology, Medical School, University of Alcalá, Madrid, Spain
| | | | | |
Collapse
|